메뉴 건너뛰기




Volumn 12, Issue 5, 2012, Pages 618-627

Cognitive impairment in multiple sclerosis

Author keywords

Amphetamine; Assessment; Cholinesterase inhibitors; Cognitive impairment; Cognitive rehabilitation; Complementary and alternative treatments; Cortical pathology; Disease modifying therapies(DMTs); Domains of impairment; Exercise; FMRI; Functional connectivity; Imaging correlates of MS; Incidence; Interferon; Lesion load; Memory; MRI; Multiple sclerosis (MS); Neuropsychological tests; Prevalence; Processing speed; Symptomatic treatment; Theory of mind; Yoga

Indexed keywords

AMPHETAMINE; BETA1A INTERFERON; CHOLINESTERASE INHIBITOR; DONEPEZIL; FINGOLIMOD; GINKGO BILOBA EXTRACT; GLATIRAMER; INTERFERON BETA SERINE; MEMANTINE; METHYLPHENIDATE; MODAFINIL; NATALIZUMAB; PLACEBO; RIVASTIGMINE;

EID: 84870523440     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0294-3     Document Type: Review
Times cited : (52)

References (53)
  • 1
    • 79958223011 scopus 로고    scopus 로고
    • Risk factors for and management of cognitive dysfunction in multiple sclerosis
    • Important recent review on CI in MS
    • Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7:332-42. Important recent review on CI in MS.
    • (2011) Nat Rev Neurol. , vol.7 , pp. 332-342
    • Benedict, R.H.1    Zivadinov, R.2
  • 2
    • 79952842934 scopus 로고    scopus 로고
    • Cognitive functioning in multiple sclerosis
    • Important recent review on CI in MS
    • Julian LJ. Cognitive functioning in multiple sclerosis. Neurol Clin. 2011;29:507-25. Important recent review on CI in MS.
    • (2011) Neurol Clin. , vol.29 , pp. 507-525
    • Julian, L.J.1
  • 3
    • 0025731153 scopus 로고
    • Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction
    • Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology. 1991;41:685-91.
    • (1991) Neurology. , vol.41 , pp. 685-691
    • Rao, S.M.1    Leo, G.J.2    Bernardin, L.3    Unverzagt, F.4
  • 5
    • 77649105734 scopus 로고    scopus 로고
    • Social cognition and theory of mind in patients with relapsing-remitting multiple sclerosis
    • Banati M, Sandor J, Mike A, et al. Social cognition and theory of mind in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2009;17:426-33.
    • (2009) Eur J Neurol. , vol.17 , pp. 426-433
    • Banati, M.1    Sandor, J.2    Mike, A.3
  • 6
    • 80355147073 scopus 로고    scopus 로고
    • Cognitively preserved MS patients demonstrate functional differences in processing neutral and emotional faces
    • Interesting new findings on the changes in cortical networks responsible theory of mind processes in patients with MS
    • Jehna M, Langkammer C, Wallner-Blazek M, et al. Cognitively preserved MS patients demonstrate functional differences in processing neutral and emotional faces. Brain Imaging Behav. 2011;5:241-51. Interesting new findings on the changes in cortical networks responsible theory of mind processes in patients with MS.
    • (2011) Brain Imaging Behav. , vol.5 , pp. 241-251
    • Jehna, M.1    Langkammer, C.2    Wallner-Blazek, M.3
  • 7
    • 0034798404 scopus 로고    scopus 로고
    • Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years
    • Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58:1602-6. (Pubitemid 32963224)
    • (2001) Archives of Neurology , vol.58 , Issue.10 , pp. 1602-1606
    • Amato, M.P.1    Ponziani, G.2    Siracusa, G.3    Sorbi, S.4
  • 8
    • 77957913088 scopus 로고    scopus 로고
    • Predicting loss of employment over three years in multiple sclerosis: Clinically meaningful cognitive decline
    • This important paper helps determine a level of change in cognitive tests that has important implications for employability and will be useful in the design of clinical trials
    • Morrow SA, Drake A, Zivadinov R, et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol. 2010;24:1131-45. This important paper helps determine a level of change in cognitive tests that has important implications for employability and will be useful in the design of clinical trials.
    • (2010) Clin Neuropsychol. , vol.24 , pp. 1131-1145
    • Morrow, S.A.1    Drake, A.2    Zivadinov, R.3
  • 9
    • 84862776791 scopus 로고    scopus 로고
    • Cognitive and motor functioning in patients with multiple sclerosis: Neuropsychological predictors of walking speed and falls
    • D'Orio VL, Foley FW, Armentano F, et al. Cognitive and motor functioning in patients with multiple sclerosis: neuropsychological predictors of walking speed and falls. J Neurol Sci. 2012;316:42-6.
    • (2012) J Neurol Sci. , vol.316 , pp. 42-46
    • D'Orio, V.L.1    Foley, F.W.2    Armentano, F.3
  • 10
    • 0033663893 scopus 로고    scopus 로고
    • Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group
    • Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48:885-92.
    • (2000) Ann Neurol. , vol.48 , pp. 885-892
    • Fischer, J.S.1    Priore, R.L.2    Jacobs, L.D.3
  • 12
    • 8844222623 scopus 로고    scopus 로고
    • Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
    • Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788-95. (Pubitemid 39532370)
    • (2004) Neurology , vol.63 , Issue.10 , pp. 1788-1795
    • Panitch, H.1
  • 14
    • 33644584352 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    • Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
    • (2006) N Engl J Med. , vol.354 , pp. 899-910
    • Polman, C.H.1    O'Connor, P.W.2    Havrdova, E.3
  • 15
    • 33644608613 scopus 로고    scopus 로고
    • Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    • Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23.
    • (2006) N Engl J Med. , vol.354 , pp. 911-923
    • Rudick, R.A.1    Stuart, W.H.2    Calabresi, P.A.3
  • 16
    • 84862521049 scopus 로고    scopus 로고
    • Additional efficacy endpoints from pivotal natalizumab trials in relapsingremitting MS
    • Important although limited assessment of the impact of Natalizumab on CI
    • Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsingremitting MS. J Neurol. 2012;259:898-905. Important although limited assessment of the impact of Natalizumab on CI.
    • (2012) J Neurol. , vol.259 , pp. 898-905
    • Weinstock-Guttman, B.1    Galetta, S.L.2    Giovannoni, G.3
  • 17
    • 84856052310 scopus 로고    scopus 로고
    • Natalizumab may improve cognition and mood in multiple sclerosis
    • Lang C, Reiss C, Maurer M. Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol. 2012;67:162-6.
    • (2012) Eur Neurol. , vol.67 , pp. 162-166
    • Lang, C.1    Reiss, C.2    Maurer, M.3
  • 18
    • 79551600627 scopus 로고    scopus 로고
    • The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: Preliminary results of a 1-year follow-up study
    • Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci. 2011;32:83-8.
    • (2011) Neurol Sci. , vol.32 , pp. 83-88
    • Mattioli, F.1    Stampatori, C.2    Capra, R.3
  • 19
    • 78449297684 scopus 로고    scopus 로고
    • Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks
    • Morrow SA, O'Connor PW, Polman CH, et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010;16:1385-92.
    • (2010) Mult Scler. , vol.16 , pp. 1385-1392
    • Morrow, S.A.1    O'Connor, P.W.2    Polman, C.H.3
  • 20
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362 (5):402-15.
    • (2010) N Engl J Med. , vol.362 , Issue.5 , pp. 402-415
    • Cohen, J.A.1    Barkhof, F.2    Comi, G.3
  • 21
    • 76149093586 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    • Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
    • (2010) N Engl J Med. , vol.362 , pp. 387-401
    • Kappos, L.1    Radue, E.W.2    O'Connor, P.3
  • 23
    • 73949111235 scopus 로고    scopus 로고
    • Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis
    • Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009;16:68-77.
    • (2009) Mult Scler. , vol.16 , pp. 68-77
    • Patti, F.1    Amato, M.P.2    Bastianello, S.3
  • 24
    • 54449092493 scopus 로고    scopus 로고
    • Memory decline evolves independently of disease activity inMS
    • Duque B, Sepulcre J, Bejarano B, et al. Memory decline evolves independently of disease activity inMS. Mult Scler. 2008;14:947-53.
    • (2008) Mult Scler. , vol.14 , pp. 947-953
    • Duque, B.1    Sepulcre, J.2    Bejarano, B.3
  • 25
    • 84863528052 scopus 로고    scopus 로고
    • Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis
    • Brooks JB, Borela MC, Fragoso YD. Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr. 2012;69:887-91.
    • (2012) Arq Neuropsiquiatr. , vol.69 , pp. 887-891
    • Brooks, J.B.1    Borela, M.C.2    Fragoso, Y.D.3
  • 26
    • 79251621746 scopus 로고    scopus 로고
    • Cognitive function and quality of life in multiple sclerosis patients: A crosssectional study
    • Baumstarck-Barrau K, Simeoni MC, Reuter F, et al. Cognitive function and quality of life in multiple sclerosis patients: a crosssectional study. BMC Neurol. 2011;11:17.
    • (2011) BMC Neurol. , vol.11 , pp. 17
    • Baumstarck-Barrau, K.1    Simeoni, M.C.2    Reuter, F.3
  • 27
    • 84869204634 scopus 로고    scopus 로고
    • Verbal episodic memory in 426 multiple sclerosis patients: Impairment in encoding, retrieval or both?
    • Brissart H, Morele E, Baumann C, Debouverie M. Verbal episodic memory in 426 multiple sclerosis patients: impairment in encoding, retrieval or both? Neurol Sci. 2012.
    • (2012) Neurol Sci.
    • Brissart, H.1    Morele, E.2    Baumann, C.3    Debouverie, M.4
  • 28
    • 84155165482 scopus 로고    scopus 로고
    • Cognitive deterioration in patients with early multiple sclerosis: A 5-year study
    • Glanz BI, Healy BC, Hviid LE, et al. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2011;83:38-43.
    • (2011) J Neurol Neurosurg Psychiatry. , vol.83 , pp. 38-43
    • Glanz, B.I.1    Healy, B.C.2    Hviid, L.E.3
  • 30
    • 58149093385 scopus 로고    scopus 로고
    • Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome
    • Kocer B, Unal T, Nazliel B, et al. Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome. Neurol Sci. 2008;29:435-44.
    • (2008) Neurol Sci. , vol.29 , pp. 435-444
    • Kocer, B.1    Unal, T.2    Nazliel, B.3
  • 31
    • 0026746069 scopus 로고
    • Clinically isolated lesions of the type seen in multiple sclerosis: A cognitive, psychiatric, and MRI follow up study
    • Feinstein A, Kartsounis LD, Miller DH, et al. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry. 1992;55:869-76.
    • (1992) J Neurol Neurosurg Psychiatry. , vol.55 , pp. 869-876
    • Feinstein, A.1    Kartsounis, L.D.2    Miller, D.H.3
  • 32
    • 80052643569 scopus 로고    scopus 로고
    • Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis
    • Reuter F, Zaaraoui W, Crespy L, et al. Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;82:1157-9.
    • (2010) J Neurol Neurosurg Psychiatry. , vol.82 , pp. 1157-1159
    • Reuter, F.1    Zaaraoui, W.2    Crespy, L.3
  • 33
    • 77955149438 scopus 로고    scopus 로고
    • Cognitive function in radiologically isolated syndrome
    • This interesting study documents the presence of cognitive changes before other symptoms occur among people with incidental findings of brain lesions typical of MS
    • Lebrun C, Blanc F, Brassat D, et al. Cognitive function in radiologically isolated syndrome. Mult Scler. 2010;16:919-25. This interesting study documents the presence of cognitive changes before other symptoms occur among people with incidental findings of brain lesions typical of MS.
    • (2010) Mult Scler. , vol.16 , pp. 919-925
    • Lebrun, C.1    Blanc, F.2    Brassat, D.3
  • 34
    • 84858046933 scopus 로고    scopus 로고
    • Association of MRI metrics and cognitive impairment in radiologically isolated syndromes
    • Another recent interesting study documenting CI in patients with RIS
    • Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology. 2012;78:309-14. Another recent interesting study documenting CI in patients with RIS.
    • (2012) Neurology. , vol.78 , pp. 309-314
    • Amato, M.P.1    Hakiki, B.2    Goretti, B.3
  • 35
    • 84860803647 scopus 로고    scopus 로고
    • Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis
    • This study clarifies the long-standing paradox of why lesion burden does not correlate with CI
    • Mesaros S, Rocca MA, Kacar K, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology. 2012;78:969-75. This study clarifies the long-standing paradox of why lesion burden does not correlate with CI.
    • (2012) Neurology. , vol.78 , pp. 969-975
    • Mesaros, S.1    Rocca, M.A.2    Kacar, K.3
  • 36
    • 82755187740 scopus 로고    scopus 로고
    • Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis
    • This study documents changes in the default and control networks in patients with MS and correlates these changes with CI
    • Hawellek DJ, Hipp JF, Lewis CM, et al. Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis. Proc Natl Acad Sci U S A. 2011;108:19066-71. This study documents changes in the default and control networks in patients with MS and correlates these changes with CI.
    • (2011) Proc Natl Acad Sci U S A. , vol.108 , pp. 19066-19071
    • Hawellek, D.J.1    Hipp, J.F.2    Lewis, C.M.3
  • 37
    • 77956333880 scopus 로고    scopus 로고
    • Efficacy of an executive function intervention programme in MS: A placebo-controlled and pseudorandomized trial
    • Fink F, Rischkau E, Butt M, et al. Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudorandomized trial. Mult Scler. 2010;16:1148-51.
    • (2010) Mult Scler. , vol.16 , pp. 1148-1151
    • Fink, F.1    Rischkau, E.2    Butt, M.3
  • 38
    • 13844309632 scopus 로고    scopus 로고
    • Treating learning impairments improves memory performance in multiple sclerosis: A randomized clinical trial
    • DOI 10.1191/1352458505ms1118oa
    • Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult Scler. 2005;11:58-68. (Pubitemid 40259976)
    • (2005) Multiple Sclerosis , vol.11 , Issue.1 , pp. 58-68
    • Chiaravalloti, N.D.1    DeLuca, J.2    Moore, N.B.3    Ricker, J.H.4
  • 39
    • 84866367486 scopus 로고    scopus 로고
    • A randomized controlled trial of a cognitive rehabilitation intervention for persons with multiple sclerosis
    • This study shows promising results from cognitive rehabilitation strategy
    • Stuifbergen AK, Becker H, Perez F, et al. A randomized controlled trial of a cognitive rehabilitation intervention for persons with multiple sclerosis. Clin Rehabil. 2012. This study shows promising results from cognitive rehabilitation strategy.
    • (2012) Clin Rehabil.
    • Stuifbergen, A.K.1    Becker, H.2    Perez, F.3
  • 40
    • 58149148227 scopus 로고    scopus 로고
    • Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process
    • Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci. 2009;276:38-40.
    • (2009) J Neurol Sci. , vol.276 , pp. 38-40
    • Harel, Y.1    Appleboim, N.2    Lavie, M.3    Achiron, A.4
  • 41
    • 50049122115 scopus 로고    scopus 로고
    • Effects of lamphetamine sulfate on cognitive function in multiple sclerosis patients
    • Benedict RH, Munschauer F, Zarevics P, et al. Effects of lamphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol. 2008;255:848-52.
    • (2008) J Neurol. , vol.255 , pp. 848-852
    • Benedict, R.H.1    Munschauer, F.2    Zarevics, P.3
  • 42
    • 84860413311 scopus 로고    scopus 로고
    • L-amphetamine improves memory in MS patients with objective memory impairment
    • Sumowski JF, Chiaravalloti N, Erlanger D, et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler. 2011;17:1141-5.
    • (2011) Mult Scler. , vol.17 , pp. 1141-1145
    • Sumowski, J.F.1    Chiaravalloti, N.2    Erlanger, D.3
  • 43
    • 72949121422 scopus 로고    scopus 로고
    • Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil
    • Wilken JA, Sulliven C, Wallin M, et al. Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil. Int J MS Care. 2008;10:1-10.
    • (2008) Int J MS Care. , vol.10 , pp. 1-10
    • Wilken, J.A.1    Sulliven, C.2    Wallin, M.3
  • 44
    • 80052010239 scopus 로고    scopus 로고
    • HAGIL (Hamburg Vigil Study): A randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis
    • Moller F, Poettgen J, Broemel F, et al. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler. 2011;17:1002-9.
    • (2011) Mult Scler. , vol.17 , pp. 1002-1009
    • Moller, F.1    Poettgen, J.2    Broemel, F.3
  • 45
    • 80655128163 scopus 로고    scopus 로고
    • The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue
    • Huolman S, Hamalainen P, Vorobyev V, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler. 2011;17:1351-61.
    • (2011) Mult Scler. , vol.17 , pp. 1351-1361
    • Huolman, S.1    Hamalainen, P.2    Vorobyev, V.3
  • 47
    • 79955502336 scopus 로고    scopus 로고
    • Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
    • This is an important randomized placebo-controlled trial that, unfortunately, showed no benefit with donepezil
    • Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011;76:1500-7. This is an important randomized placebo-controlled trial that, unfortunately, showed no benefit with donepezil.
    • (2011) Neurology. , vol.76 , pp. 1500-1507
    • Krupp, L.B.1    Christodoulou, C.2    Melville, P.3
  • 48
    • 67049100685 scopus 로고    scopus 로고
    • Memantine induces reversible neurologic impairment in patients with MS
    • Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009;72:1630-3.
    • (2009) Neurology. , vol.72 , pp. 1630-1633
    • Villoslada, P.1    Arrondo, G.2    Sepulcre, J.3
  • 49
    • 77953733410 scopus 로고    scopus 로고
    • Memantine for cognitive impairment in multiple sclerosis: A randomized placebo-controlled trial
    • Our randomized multicenter trial with memantine also failed to show any beneficial effect
    • Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16:715-23. Our randomized multicenter trial with memantine also failed to show any beneficial effect.
    • (2010) Mult Scler. , vol.16 , pp. 715-723
    • Lovera, J.F.1    Frohman, E.2    Brown, T.R.3
  • 51
    • 84870512209 scopus 로고    scopus 로고
    • Randomized placebo controlled trial of Ginkgo biloba for cognitive impairment in multiple sclerosis
    • Lovera J, Howieson D, Wild K, et al. Randomized placebo controlled trial of Ginkgo biloba for cognitive impairment in multiple sclerosis. Neurology 2011 Suppl 4: A546
    • Neurology 2011 Suppl , vol.4
    • Lovera, J.1    Howieson, D.2    Wild, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.